The occurrence of SF3B1 mutation in CLL patients is found to increase with the course of the disease, the maximum incidence being at the treatment phase or in chemorefractory CLL, indicating that SF3B1 mutations may be acquired during therapy [32]. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.